Schiffer CA - Search Results

1

Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.

Hensley ML, Peterson B, Silver RT, Larson RA, Schiffer CA, Szatrowski TP. Hensley ML, et al. Among authors: schiffer ca. J Clin Oncol. 2000 Mar;18(6):1301-8. doi: 10.1200/JCO.2000.18.6.1301. J Clin Oncol. 2000. PMID: 10715301

2

Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).

Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, Wurster-Hill DH, Sobol RE, Schiffer C, Bloomfield CD. Westbrook CA, et al. Among authors: schiffer c. Blood. 1992 Dec 15;80(12):2983-90. Blood. 1992. PMID: 1467514 Free article. Clinical Trial.

3

Cancer and Leukemia Group B (CALGB) studies in adult acute lymhocytic leukemia.

Schiffer CA, Larson RA, Bloomfield CD. Schiffer CA, et al. Leukemia. 1992;6 Suppl 2:171-4. Leukemia. 1992. PMID: 1578925 Review. No abstract available.

4

Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.

Rubin EH, Andersen JW, Berg DT, Schiffer CA, Mayer RJ, Stone RM. Rubin EH, et al. Among authors: schiffer ca. J Clin Oncol. 1992 Jun;10(6):948-53. doi: 10.1200/JCO.1992.10.6.948. J Clin Oncol. 1992. PMID: 1588374 Clinical Trial.

5

The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B.

Ellison RR, Mick R, Cuttner J, Schiffer CA, Silver RT, Henderson ES, Woliver T, Royston I, Davey FR, Glicksman AS, et al. Ellison RR, et al. Among authors: schiffer ca. J Clin Oncol. 1991 Nov;9(11):2002-15. doi: 10.1200/JCO.1991.9.11.2002. J Clin Oncol. 1991. PMID: 1941059 Clinical Trial.

6

Interferon studies in the treatment of patients with leukemia.

Schiffer CA. Schiffer CA. Semin Oncol. 1991 Oct;18(5 Suppl 7):1-6. Semin Oncol. 1991. PMID: 1948122 Review.

7

Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B.

Mayer RJ, Schiffer CA, Peterson BA, Budman DR, Silver RT, Rai KR, Cornwell GG, Ellison RR, Maguire M, Berg DT, et al. Mayer RJ, et al. Among authors: schiffer ca. Semin Oncol. 1987 Jun;14(2 Suppl 1):25-31. Semin Oncol. 1987. PMID: 3296206 Clinical Trial. No abstract available.

8

Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study.

Schiffer CA, Davis RB, Mayer RJ, Peterson BA, Lee EJ. Schiffer CA, et al. Cancer Treat Rep. 1987 Sep;71(9):879-80. Cancer Treat Rep. 1987. PMID: 3621225 No abstract available.

9

Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study.

Mayer RJ, Schiffer CA, Peterson BA, Silver RT, Cornwell GG, McIntyre OR, Rai KR, Budman DR, Ellison RR, Maguire M, et al. Mayer RJ, et al. Among authors: schiffer ca. Semin Oncol. 1985 Jun;12(2 Suppl 3):84-90. Semin Oncol. 1985. PMID: 4012343 No abstract available.

10

Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B.

Rai KR, Davey F, Peterson B, Schiffer C, Silver RT, Ozer H, Golomb H, Bloomfield CD. Rai KR, et al. Leukemia. 1995 Jul;9(7):1116-20. Leukemia. 1995. PMID: 7630181 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

546 results

Search Page